211 related articles for article (PubMed ID: 36413364)
81. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
82. The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.
Zargar H; van den Bergh R; Moon D; Lawrentschuk N; Costello A; Murphy D
BJU Int; 2017 Jan; 119(1):110-115. PubMed ID: 27454454
[TBL] [Abstract][Full Text] [Related]
83. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?
Sirovich BE; Schwartz LM; Woloshin S
JAMA; 2003 Mar; 289(11):1414-20. PubMed ID: 12636464
[TBL] [Abstract][Full Text] [Related]
84. Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial.
Barocas DA; Grubb R; Black A; Penson DF; Fowke JH; Andriole G; Crawford ED
Cancer; 2013 Jun; 119(12):2223-9. PubMed ID: 23559420
[TBL] [Abstract][Full Text] [Related]
85. Impact of health literacy on shared decision making for prostate-specific antigen screening in the United States.
Nguyen DD; Trinh QD; Cole AP; Kilbridge KL; Mahal BA; Hayn M; Hansen M; Han PKJ; Sammon JD
Cancer; 2021 Jan; 127(2):249-256. PubMed ID: 33165954
[TBL] [Abstract][Full Text] [Related]
86. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.
Hayes JH; Barry MJ
JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604
[TBL] [Abstract][Full Text] [Related]
87. Medication Adherence, Health Care Utilization, and Spending Among Privately Insured Adults With Chronic Conditions in the United States, 2010-2016.
Gillespie CW; Morin PE; Tucker JM; Purvis L
Am J Med; 2020 Jun; 133(6):690-704.e19. PubMed ID: 31987798
[TBL] [Abstract][Full Text] [Related]
88. Trends in Prostate-specific Antigen Screening, Prostate Biopsies, Urology Visits, and Prostate Cancer Treatments From 2000 to 2012.
Wallner LP; Hsu JW; Loo RK; Palmer-Toy DE; Schottinger JE; Jacobsen SJ
Urology; 2015 Sep; 86(3):498-505. PubMed ID: 26123517
[TBL] [Abstract][Full Text] [Related]
89. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
[TBL] [Abstract][Full Text] [Related]
90. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
91. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
Drazer MW; Prasad SM; Huo D; Schonberg MA; Dale W; Szmulewitz RZ; Eggener SE
Cancer; 2014 May; 120(10):1491-8. PubMed ID: 24523016
[TBL] [Abstract][Full Text] [Related]
92. Factors Related to Prostate-Specific Antigen-Based Prostate Cancer Screening in Primary Care: Retrospective Cohort Study of 120,587 French Men Over the Age of 50 Years.
Rat C; Schmeltz H; Rocher S; Nanin F; Gaultier A; Nguyen JM
JMIR Public Health Surveill; 2018 Oct; 4(4):e10352. PubMed ID: 30355559
[TBL] [Abstract][Full Text] [Related]
93. The effect of limited english proficiency on prostate-specific antigen screening in American men.
Stone BV; Labban M; Beatrici E; Filipas DK; Frego N; Qian ZJ; Voleti SS; Osman NY; Pomerantz MM; Lipsitz SR; Feldman AS; Kibel AS; Cole AP; Trinh QD
World J Urol; 2024 Jan; 42(1):54. PubMed ID: 38244128
[TBL] [Abstract][Full Text] [Related]
94. Prostate Specific Antigen Testing Behaviors for Prostate Cancer Screening Among U.S. Immigrants: A Cross-sectional Analysis Using the National Health Interview Survey.
Hansen NF; Linscott JA; Hayn MH; Ryan ST; Sammon JD
J Urol; 2023 Jan; 209(1):161-169. PubMed ID: 36250952
[TBL] [Abstract][Full Text] [Related]
95. Spatial patterns of prostate-specific antigen testing in asymptomatic men across Australia: a population-based cohort study, 2017-2018.
Kohar A; Cramb SM; Pickles K; Smith DP; Baade PD
Public Health; 2023 Apr; 217():173-180. PubMed ID: 36898290
[TBL] [Abstract][Full Text] [Related]
96. Low-value care and excess out-of-pocket expenditure among older adults with incident cancer - A machine learning approach.
Iloabuchi C; Dwibedi N; LeMasters T; Shen C; Ladani A; Sambamoorthi U
J Cancer Policy; 2021 Dec; 30():100312. PubMed ID: 35559807
[TBL] [Abstract][Full Text] [Related]
97. Using Behavioral Economics to Reduce Low-Value Care Among Older Adults: A Cluster Randomized Clinical Trial.
Kullgren JT; Kim HM; Slowey M; Colbert J; Soyster B; Winston SA; Ryan K; Forman JH; Riba M; Krupka E; Kerr EA
JAMA Intern Med; 2024 Mar; 184(3):281-290. PubMed ID: 38285565
[TBL] [Abstract][Full Text] [Related]
98. Care cascades following low-value cervical cancer screening in dually enrolled Veterans.
Pickering AN; Zhao X; Sileanu FE; Lovelace EZ; Rose L; Schwartz AL; Hale JA; Schleiden LJ; Gellad WF; Fine MJ; Thorpe CT; Radomski TR
J Am Geriatr Soc; 2024 May; ():. PubMed ID: 38721922
[TBL] [Abstract][Full Text] [Related]
99. PSA testing in older men adds unnecessary expenditures to Medicare Advantage plans.
Nierengarten MB
Cancer; 2023 Apr; 129(7):980. PubMed ID: 36883853
[No Abstract] [Full Text] [Related]
100. Prostate-specific Antigen Testing in Men with Disabilities: A Cross-sectional Analysis of the Health Information National Trends Survey.
Leong JY; Pinkhasov R; Chandrasekar T; Shapiro O; Daneshvar M; Jacob J; Sanford T; Bratslavsky G; Goldberg H
Eur Urol Focus; 2022 Sep; 8(5):1125-1132. PubMed ID: 34332951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
